Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
BioMarin Pharmaceutical Inc. - Common Stock
(NQ:
BMRN
)
57.82
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about BioMarin Pharmaceutical Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
↗
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
↗
September 05, 2024
BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enhance growth.
Via
Benzinga
Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
↗
September 05, 2024
Via
Benzinga
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
↗
September 04, 2024
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow...
Via
Benzinga
NASDAQ:BMRN is showing good growth, while it is not too expensive.
↗
September 04, 2024
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced.
Via
Chartmill
(BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
↗
August 21, 2024
Via
Benzinga
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
↗
August 20, 2024
Via
Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
↗
July 24, 2024
BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock which is not overvalued.
Via
Chartmill
Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
↗
August 24, 2024
What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Aug. 19-23, 2024.
Via
Talk Markets
Palo Alto Networks To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Tuesday
↗
August 20, 2024
Via
Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
↗
August 14, 2024
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable.
Via
Chartmill
$1000 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
↗
August 07, 2024
Via
Benzinga
Rare Disease-Focused BioMarin Narrows Sales Focus, Cuts Cost For Hemophilia A Gene Therapy; Lifts Annual Guidance
↗
August 06, 2024
BioMarin Pharmaceutical shifts focus to commercial operations for Roctavian in the U.S., Germany, and Italy. Projected cost reductions aim to achieve profitability by 2025. Strong Q2 performance driven...
Via
Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $16,000 Today
↗
July 16, 2024
Via
Benzinga
Peering Into Biomarin Pharmaceutical's Recent Short Interest
↗
July 04, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
↗
June 27, 2024
Via
Benzinga
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday
↗
August 06, 2024
Via
Benzinga
Biomarin Pharmaceutical Analysts Boost Their Forecasts Following Better-Than-Expected Q2 Results
↗
August 06, 2024
Via
Benzinga
BMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
↗
August 05, 2024
BMRN stock results show that Biomarin Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts
↗
July 22, 2024
Via
Benzinga
$100 Invested In Biomarin Pharmaceutical 20 Years Ago Would Be Worth This Much Today
↗
July 18, 2024
Via
Benzinga
Looking Into Biomarin Pharmaceutical's Recent Short Interest
↗
May 28, 2024
Via
Benzinga
NASDAQ:BMRN is not too expensive for the growth it is showing.
↗
May 21, 2024
Looking for growth without the hefty price tag? Consider BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN).
Via
Chartmill
Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
↗
July 02, 2024
Investors should take note ofBIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), a growth stock that remains attractively priced.
Via
Chartmill
For those who appreciate growth without the sticker shock, NASDAQ:BMRN is worth considering.
↗
June 11, 2024
While growth is established for BIOMARIN PHARMACEUTICAL INC (NASDAQ:BMRN), the stock's valuation remains reasonable.
Via
Chartmill
CrowdStrike, KKR, GoDaddy To Join S&P 500 In Quarterly Rebalance; Stocks Jump
↗
June 07, 2024
KKR and GoDaddy also will join before the open on June 24.
Via
Investor's Business Daily
Topics
Stocks
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
↗
June 05, 2024
Biotech surge alert! Discover three biotech stocks to buy as they catch up with the market in the rest of 2024.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
↗
June 04, 2024
Via
Benzinga
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results
↗
June 04, 2024
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine.
Via
Investor's Business Daily
Li Auto Was One Of The Worst-Performing Stocks Last Week: Are These 10 Large-Cap Stocks Losers In Your Portfolio? (May 12-May 18, 2024)
↗
May 19, 2024
Last week, these 10 large-cap stocks had the worst performance. NICE, PBR, FIX, LI, MLM, VMC, BMRN, EDU, GFI, MUFG all saw significant decreases.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
